comparison with the HC. The latter PSD analysis resulted positively correlated with ESR (p<0.01; r=-0.5) and CRP values (p<0.001; r=-0.4). FP mean differential sensitivity and FP mean defect values were lower in PsA patients with respect to HC (p<0.0001 for both the comparisons, figure 1E-F) and resulted negatively correlated with the age (p<0.03 r=-0.4 for both the correlations, figure 1G-H). SD-OCT in the posterior pole (superior and inferior hemifields) did not reveal differences for the mean retinal thickness between PsA patients and HC.

Conclusions: Intriguingly, an impairment in quality of tear film in PsA patients was observed compared to HC. The correlation between ESR and dry eye tests may be explained with a potential relationship between systemic inflammation and sicca syndrome.

Interestingly, PsA patients showed a reduced functional impairment by reduced retinal sensitivity measured by MD, FP mean differential sensitivity and FP mean defect values.

To our knowledge this is the first study investigating eye function and morphology in PsA patients. Further studies are needed to confirm and explain these results.

Disclosure of Interest: None declared


SAT0309 UNDERESTIMATION OF CARDIOVASCULAR EVENTS BY CARDIOVASCULAR RISK SCORES IN PSORIATIC ARTHRITIS PATIENTS

M. Lam1, S.H.O. Ng1, S.H. Cho1, T.K. Chun1, L.K. Kot1, C.T. Yin1, E.F. Yu1, E.W.L. Kung1, L.S. Tam1. 1Department of Medicine and Therapeutics, THE CHINESE UNIVERSITY OF HONG KONG, Sha Tin; 2Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong

Background: Compared with the general population, patients with Psoriatic Arthritis (PsA) have elevated risks of developing cardiovascular diseases (CVD). The performances of established CVD risk scores in PsA patients have not been fully evaluated yet. European League Against Rheumatism (EULAR) recommends a 1.5 multiplication factor to these CVD risk scores when it is applied in rheumatoid arthritis patients. Whether the same multiplication factor could improve the performance of the risk scores in PsA patients is unknown.

Objectives: To investigate the performances of various CVD risk scores and their EULAR modified versions for predicting CVD events in PsA patients.

Methods: Prospectively collected data from the two Hong Kong PsA cohort was used. Discriminatory ability for CV risk prediction was estimated by the area under the receiver operating characteristic curve (AUC). Four different CVD risk scores were calculated at baseline. The primary outcome was first CVD events, including acute coronary syndrome, stable and unstable angina, myocardial infarction, ischaemic and haemorrhagic stroke, transient ischaemic attack, heart failure, coronary insufficiency, peripheral arterial disease, thrombosis, percutaneous coronary intervention (angioplasty), coronary artery bypass graft, implantaion of pacemaker or defibrillator and CVD death.

Results: 228 patients (48.9±11.8 years, male: 124 (54.4%)) were recruited between 2006 to 2016. Baseline data were available from 227, 226, 226 and 188 patients to calculate the FRS, QRISKII, HeartScore and ASCVD, respectively. After a mean follow up of 6.7±4.7 years, 30 patients (13.2%) experienced a CVD event (CVD +group). At baseline, the CVD +group was significantly older (57.8 ±12.0 years vs 47.6±11.2 years; p<0.001), had higher systolic blood pressure (SBP: 142±22.0 vs 128 ±19.6 mmHg; p<0.001) and higher triglycerides (TG: 1.8±1.3 vs 1.4±0.8 mmol/L; p=0.027), All CVD risk scores were significantly higher in the CVD +group (FRS: 18.2±13.1 vs 12.9±8.7; p<0.001; QRISKII: 11.9±8.6 vs 4.9±5.0; p<0.001; Heart-Score: 2.3±2.1 vs 0.9±1.3; p<0.001; ASCVD: 14.5±12.8 vs 4.8±5.2; p<0.001). AUC for FRS, QRISKII, HeartScore and ASCVD were 0.74 (0.64–0.83; p<0.001), 0.76 (0.66–0.86; p<0.001), 0.72 (0.62–0.83; p<0.001), and 0.77 (0.67–0.86; p<0.001), respectively. In total, 76 (33.5%), 9 (4.0%), 7 (3.1%) and 47 (25.0%) patients were classified as high CVD risk according to FRS >10%, QRISK >20%, HeartScore >5% and ASCVD >7.5% respectively. In the CVD +group, those identified as high risk were only 63% (by FRS), 20% (by QRISK), 13.3% (by Heart-Score) and 46% (by ASCVD) (figure1A). By applying the EULAR multiplication factor, 80%, 36%, 26.67% and 56.7% of the patients with CVD + were reclassified as high risk (figure1B).

Conclusions: All CVD risk scores significantly underestimated CVD risks among PsA patients. This study demonstrated for the first time that adaptation of the EULAR recommendation only improved the accuracy of FRS to a moderate level.

Disclosure of Interest: None declared


SAT0310 THE ASSOCIATIONS OF SERUM IL18 AND OSTEOPROTEGERIN (OPG) LEVELS WITH THE LIPID PROFILE IN PSORIATIC ARTHRITIS (PSA) PATIENTS

K. Bonek1, P. Gluszko1, E. Kontry2. 1Department of Rheumatology; 2Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland

Background: We have previously found that IL-18 and OPG serum concentrations are correlated with cardiovascular (CV) risk in psoriatic arthritis but not in anklyosing spondylitis (AS) patients.

Objectives: To investigate whether in PsA patients the association of OPG and IL-18 with CV risk is mediated by an impact of these cytokines on lipid profile changes.

Methods: 49 patients with PsA (25 M/24 F) with (n=10) and without (n=39) coronary heart disease (CHD), and 25 sex and age matched (mean age 44.4 vs 43.4 years) patients with AS were enrolled. Disease activity was measured by DAPSA (25, 17±18.9) in PsA group and by BASDAI (5.37±2) and ASDAS- CRP (3.18±1) in AS group. The lipid profile (triglycerides – TG, total cholesterol – TC, low- and high-density lipoprotein – LDL and HDL, respectively), systemic inflammation markers and cytokines (OPG, IL-18) were measured in patients serum samples. Atherogenic index (AI=TC/HDLC) was calculated. Statistical analysis was performed using Mann-Whitney U-test and Spearman’s Rank test. Data are expressed as mean values.

Results: Patients with PsA presented more atherogenic lipid profile than AS patients because of their higher TG levels (153 vs 126.6 mg/dl; p=0.05) and AI values (3.83 vs 3.24; p=0.05) while lower HDL concentrations (51.6 vs 61.4 mg/
OVERT CARDIAC DISEASE PATIENTS WITH PSORIATIC ARTHRITIS WITHOUT INAPPROPRIATELY HIGH LEFT VENTRICULAR MASS IN PATIENTS WITH PSORIATIC ARTHRITIS WITHOUT OVERT CARDIAC DISEASE

A. Giollo1, N. Farina1, O. Orsolini1, G. Cioffi2, F. Ogniben1, L. Idolazzi1, D. Gatti1, M. Rossini1, O. Viapiana1. 1Rheumatology Unit, Department of Medicine, University of Verona, Verona, 2Department of Cardiology, Villa Bianca Hospital, Trento, Italy

Background: Early cardiovascular (CV) involvement has been found in patients with psoriatic arthritis (PsA). These patients may have a high prevalence of subclinical left ventricular (LV) dysfunction, even without established CV disease and in the absence of traditional CV risk factors. However, currently, the factors associated with LV dysfunction in PsA are unknown. Patients with inflammatory disorders are exposed to the development of excessive left ventricular mass disproportionate to the need to compensate left ventricular load, a condition named ‘inappropriately high left ventricular mass’ (iLVM). Previously, we have shown that iLVM is associated with unfavourable prognosis in patients with rheumatoid arthritis independent of traditional CV risk factors.

Objectives: In this cross-sectional study, we assessed the prevalence and factors associated with iLVM in a cohort of patients with PsA and tested the hypothesis that iLVM is per se related to LV morphology.

Methods: We evaluated 101 non-institutionalised patients>18 years of age diagnosed with PsA according to CASPAr criteria and consecutively recruited between March 2014 and December 2016. All PsA patients were free of symptoms or signs of cardiovascular disease. Patients with PsA were compared with 101 controls matched for age, sex, BMI, prevalence of hypertension and diabetes. Left ventricular chamber dimensions and wall thicknesses were measured according to the American Society of Echocardiography guidelines and predicted LVM was calculated using a validated equation considering height, sex and left ventricular work. iLVM was defined as measured/predicted LVM ratio above the 95th percentile of a reference population of healthy controls.

Results: iLVM was detected in 58% of patients with PsA and 18% of controls (p<0.001). In multivariable logistic regression analysis considering only patients with PsA, the variables independently associated with iLVM were left ventricular systolic dysfunction (LVDs) measured as mid-wall shortening and concentric left ventricular geometry. In multiple regression analyses considering the entire study population (patients with PsA and matched controls), the diagnosis of PsA was significantly associated with iLVM independent of traditional cardiovascular risk factors (OR 6.91, 95% CI 2.80–17.06, p<0.001; table 1).

Conclusions: More than 50% of patients with PsA have a disproportionate increase in their LVM. An inappropriately high LVM in PsA is associated with LV systolic dysfunction and LV concentric geometry.

REFERENCE:

Disclosure of Interest: None declared